Defining typical appearance as a goal of health service provision is harmful and unnecessary for traits that are stigmatized but neither harmful nor distressing.
AMA J Ethics. 2021;23(7):E569-575. doi:
10.1001/amajethics.2021.569.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Clinicians can practice disability humility by developing social understandings of disability. This can help clinicians improve communication and express respect for patients’ authority about their experiences.
AMA J Ethics. 2018;20(12):E1181-1187. doi:
10.1001/amajethics.2018.1181
Medical students’ moral distress about end-of-life cases can be reduced through ethics consultation and ethics rounds, narrative reflection, and mentoring.
AMA J Ethics. 2017;19(6):585-594. doi:
10.1001/journalofethics.2017.19.6.stas1-1706.
When patients express overt racism, caregivers need to feel safe and supported. The scope of organizations’ responsibilities to make that happen needs to be clearly defined.
AMA J Ethics. 2019;21(6):E499-504. doi:
10.1001/amajethics.2019.499.